Table 3.
Genetic variants showing a clear dose–response relationship in their association with ovarian cancer risk, 20.3 years of follow-up
| Main effects SNPs | Homozygous wildtype | 1 or 2 variant alleles | 1 variant allele | 2 variant alleles | p trend per allele | Benjamini–Hochberg-adjusted p value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| N cases | HR (95% CI)a | N cases | HR (95% CI)a | N cases | HR (95% CI)a | N cases | HR (95% CI)a | |||
| CAT, rs511895 | 86 | Ref | 215 | 1.25 (0.95–1.63) | 154 | 1.17 (0.88–1.56) | 61 | 1.48 (1.04–2.13) | 0.04 | 0.59 |
| CYP1A1, rs4646903 | 261 | Ref | 36 | 0.70 (0.48–1.02) | 36 | 0.70 (0.48–1.02) | na | 0.06 | 0.59 | |
| CYP1B1, rs1056827 | 144 | Ref | 154 | 1.26 (0.99–1.62) | 127 | 1.24 (0.96–1.61) | 27 | 1.36 (0.87–2.14) | 0.06 | 0.59 |
| MUTYH, rs3219489 | 189 | Ref | 112 | 0.78 (0.60–1.00) | 97 | 0.79 (0.61–1.03) | 15 | 0.70 (0.40–1.23) | 0.05 | 0.59 |
| TXN, rs2301241 | 95 | Ref | 206 | 1.26 (0.97–1.65) | 147 | 1.18 (0.89–1.56) | 59 | 1.55 (1.08–2.22) | 0.02 | 0.59 |
| GSTM1 deletion | 1 or 2 alleles present | Homozygous deletion | p value | Benjamini–Hochberg-adjusted p value | ||
|---|---|---|---|---|---|---|
| N cases | HR (95% CI)a | N cases | HR (95% CI)a | |||
| Deletion represented by | ||||||
| Both GSTM1 SNPs | 226 | Ref | 75 | 0.74 (0.56–0.98) | 0.03 | 0.59 |
| rs10857795 | 214 | Ref | 87 | 0.73 (0.56–0.95) | 0.02 | 0.59 |
| rs200184852 | 185 | Ref | 116 | 0.84 (0.66–1.09) | 0.19 | 0.59 |
aHR (95% CI): hazard ratio with corresponding 95% confidence interval; hazard ratios are adjusted for age; na not applicable